CTLA4 and neoplasm: Several inhibitory markers, including CD276, HAVCR2, CTLA4, PDCD1LG2, LAIR1, and ADORA2A, were significantly upregulated in the high-risk group (Figure 4C, p < 0.05), suggesting an immunosuppressive tumor microenvironment.